Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-R10602
- Development stage
- Phase 1
- Lead developer
- Radionetics Oncology
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-R10602 is a diagnostic radiopharmaceutical developed by Radionetics Oncology for the imaging of solid tumors, specifically hormone receptor-positive (HR+) breast cancer. It consists of a small molecule ligand, R10602, labeled with the positron-emitting radioisotope Gallium-68 (68Ga). The agent acts as a high-affinity ligand for the **Adrenomedullin 2 receptor (AM2R)**, a G-protein coupled receptor (GPCR) complex composed of the calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying protein 3 (RAMP3). AM2R is frequently overexpressed in various cancers, and 68Ga-R10602 is utilized in positron emission tomography (PET) imaging to visualize and quantify receptor expression in vivo. This imaging capability serves as a companion diagnostic to identify patients who may benefit from targeted radioligand therapy using therapeutic isotopes (such as Lutetium-177) conjugated to the same targeting ligand.
- Other names
- [68Ga]Ga-R10602
02
Targets
CXCR7 (CXC chemokine receptor 7)
Beyond the preview
Go deeper on 68Ga-R10602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-R10602.